8 completed, 5 active not recruiting, 1 recruiting, 1 terminated. 16 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 16 | Completed 8, Active not recruiting 5, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Leuprorelin: new trials by email Literature Review of Leuprorelin trials Research Report on Leuprorelin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial Abiraterone Acetate, Bicalutamide, Biospecimen Collection - Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8 | Phase 3 | Recruiting | Emory University | 72 | 2025-01-31 | 2026-02-24 |
| A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia KLH-2109, Leuprorelin - Uterine Fibroids (MeSH Heading: Leiomyoma) | Phase 3 | Completed | Kissei Pharmaceutical Co., Ltd. | 287 | 2022-10-11 | 2025-03-14 |
| Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial Bicalutamide, Buserelin, Darolutamide - Prostate Adenocarcinoma | Phase 3 | Active not recruiting | NRG Oncology | 2050 | 2021-12-06 | 2026-08-17 |
| Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial Apalutamide, Bicalutamide, Biospecimen Collection - Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8 | Phase 3 | Active not recruiting | NRG Oncology | 2753 | 2021-01-21 | 2026-08-17 |
| Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy Radiotherapy, Leuprorelin - Prostate Cancer | Phase 3 | Active not recruiting | University Medical Center Groningen | 280 | 2020-03-19 | 2025-04-04 |
| Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery Bicalutamide, Degarelix, Docetaxel - Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7 | Phase 2 / Phase 3 | Active not recruiting | NRG Oncology | 612 | 2017-04-05 | 2026-09-14 |
| A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids Relugolix, Relugolix Placebo, Leuprorelin - Uterine Fibroids | Phase 3 | Completed | Takeda | 281 | 2016-03-05 | 2019-03-22 |
| Detect V / CHEVENDO (Chemo vs. Endo) pertuzumab, Trastuzumab, Capecitabine - Metastatic Breast Cancer | Phase 3 | Unknown | Prof. Wolfgang Janni | 271 | 2015-09-01 | 2024-06-04 |
| Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) Enzalutamide, Placebo (No longer applicable in Open Label study period), Leuprolide Open Label - Hormone Sensitive Prostate Cancer, Prostate Cancer | Phase 3 | Active not recruiting | Pfizer | 1068 | 2014-12-17 | 2026-10-26 |
| A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer Leuprorelin, Bicalutamide - Prostate Cancer | Phase 3 | Completed | Takeda | 116 | 2013-06-03 | 2019-06-28 |
| PGL4001 Versus GnRH-agonist in Uterine Myomas PGL4001, leuprorelin - Uterine Myomas | Phase 3 | Completed | PregLem SA | 301 | 2008-08-01 | 2012-12-17 |
| A Study of Leuprolide to Treat Prostate Cancer Leuprolide acetate - Formulation A, Leuprolide acetate - Formulation B - Prostate Cancer | Phase 3 | Completed | Abbott | 310 | 2008-02-01 | 2011-07-19 |
| Comparison of Two Pharmacological Treatments of Pedophilia leuprorelin, Cyproterone acetate - Pedophilia | Phase 3 | Terminated | Institut National de la Santé Et de la Recherche Médicale, France | 6 | 2007-12-01 | 2026-10-28 |
| Somatropin + Leuprorelin vs Somatropin Alone in Pubertal Children With Idiopathic Short Stature somatropin, leuprorelin - Idiopathic Short Stature (ISS) | Phase 3 | Completed | Eli Lilly and Company | 91 | 2006-06-01 | 2019-09-30 |
| Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma Cyproterone acetate, Medroxyprogesterone acetate, Venlafaxine - Adenocarcinoma, Prostate | Phase 3 | Completed | Takeda | 311 | 2004-04-01 | 2015-07-30 |
| Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer Thalidomide, leuprolide acetate, goserelin - Prostate Cancer | Phase 3 | Completed | National Cancer Institute (NCI) | 159 | 2000-03-01 | 2018-05-22 |
Prostatic Neoplasms (7) · Leiomyoma (2) · Adenocarcinoma (1) · Breast Neoplasms (1) · Neoplasms (1) · Pedophilia (1)
NRG Oncology (3) · Takeda (3) · Abbott (1) · Eli Lilly and Company (1) · Emory University (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · Kissei Pharmaceutical Co., Ltd. (1) · National Cancer Institute (NCI) (1) · Pfizer (1) · PregLem SA (1) · Prof. Wolfgang Janni (1) · University Medical Center Groningen (1)
United States (7) · France (6) · Canada (4) · Netherlands (4) · Austria (2) · Germany (2) · Italy (2) · Japan (2) · Poland (2) · Spain (2) · Australia (1) · Belgium (1) · Brazil (1) · Denmark (1) · Finland (1)
Dr Elke Bestel (1) · Jens Huober, MD PhD (1) · Kristof Chwalisz, MD, PhD (1) · Mark D Hurwitz (1) · Neil B Desai (1) · Paul L Nguyen (1) · S. Al-Uwini, PhD (1) · Sagar A Patel, MD (1) · Serge Stoleru, MD, PHD (1) · William L Dahut, M.D. (1) · Yoshitaka Shimizu (1)
PMID 38421252, PMID 19167733, PMID 19963436, PMID 21518701, PMID 22025196, PMID 22296076, PMID 30741797, PMID 31899823, PMID 34385241, PMID 35501744, PMID 37119051, PMID 37851874, PMID 38320501, PMID 38421243, PMID 40140551, PMID 41124201, PMID 41349040, PMID 41364813, PMID 41698328, PMID 42333826, PMID 42406777
U10CA180868 (3), 2014 (1), P30CA138292 (1)